Type 2 DiabetesAR22NCT00652405
Effect of Alcohol on Cephalic Phase Reflex and Gene Expression
A study testing alcohol in people with Type 2 Diabetes and Inflammation, run by TNO at 1 site in Netherlands.
Trial summary
Moderate alcohol consumption has consistently been associated with lowered risk of developing type two diabetes mellitus compared to abstainers and heavy drinkers. However, the underlying mechanism for the lower risk of type two diabetes is not clear. Read more about this study
- Who is it for?
- Ages Up to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Type 2 Diabetes, Inflammation, Carbohydrate&Lipid Metabolism
- What is being tested?
- alcohol
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 24 participants
- Where
- 1 siteNetherlands
- Study dates
- May 2008to Jul 2008
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 65 years
- Women only
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Healthy as assessed by the health and lifestyle questionnaire (P8009 F02), physical examination and results of the pre-study laboratory tests
- Caucasian postmenopausal females aged 65 years or younger at Day 01 of the study.
- Body Mass Index (BMI) of 18 - 26 or 27 - 35 kg/m2.
- Postmenopausal as assessed by self reported absence of menstrual periods for at least 12 months.
- Alcohol consumption ≥ 5 and ≤ 22 standard units/week.
- Normal Dutch eating habits as assessed by P8009 F02.
Show all 11Show fewer
- Voluntary participation.
- Having given written informed consent.
- Willing to comply with the study procedures, including refrain from drinking alcoholic drinks other then the wine provided by TNO during the entire study.
- Willing to accept use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years.
- Willing to accept the disclosure of the financial benefit of participation in the study to the authorities concerned.
Who cannot join
- Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study.
- Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances.
- Having a history of medical or surgical events that may significantly affect the study outcome, particularly metabolic or endocrine disease and gastrointestinal disorders.
- Use of medication that may affect the outcome of the study parameters.
- Having a family history of alcoholism.
- Smoking.
Show all 16Show fewer
- Not having appropriate veins for blood sampling/cannula insertion according to TNO.
- Reported unexplained weight loss or gain in the month prior to the pre-study screening.
- Reported slimming or medically prescribed diet.
- Reported vegan, vegetarian or macrobiotic.
- Recent blood donation (<1 month prior to the start of the study).
- Not willing to give up blood donation during the study.
- Personnel of TNO Quality of Life, their partner and their first and second degree relatives.
- Not having a general practitioner.
- Not willing to accept information transfer concerning participation in the study, or information regarding her health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner.
- Not willing your general practitioner to be notified upon participation in this study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Moderate Alcohol Consumption on Cephalic Phase Reflex and Gene Expression of Adipose Tissue in Postmenopausal Women
Moderate alcohol consumption has consistently been associated with lowered risk of developing type two diabetes mellitus compared to abstainers and heavy drinkers. However, the underlying mechanism for the lower risk of type two diabetes is not clear.
Hypothesis: moderate alcohol consumption for four weeks changes gene expression pathways of inflammatory status, insulin sensitivity and lipid and carbohydrate metabolism in adipose tissue in both lean and obese postmenopausal women.
Hypothesis: Oral sensory stimulation by means of alcohol in the oral cavity will induce a cephalic phase reflex as indicated by increased autonomic \& endocrine responses in postmenopausal women.
Read the detailed description
Moderate alcohol consumption has consistently been associated with lowered risk of developing type two diabetes mellitus compared to abstainers and heavy drinkers. However, the physiological mechanism for this is not known.
Two potential mechanisms will be investigated in this study to explain the findings from observational studies: One concerning more acute changes upon alcohol consumption (cephalic phase reflex) which could explain the observed improvement in postprandial glycemia after alcohol consumption; the other has to do with metabolic changes after more prolonged moderate alcohol consumption in gene expression of adipose tissue which might lead to improved insulin sensitivity. Both mechanisms will be discussed below.
Cephalic phase reflex Mere exposure to smell, sight, taste and textural attributes of foods elicits myriad digestive, endocrinologic, thermogenic, cardiovascular and renal responses. These responses are rapid (generally occurring in minutes of sensory stimulation), small (relative to the magnitude achieved when food is actually being metabolized) and transient (retuning to baseline levels within minutes). They are termed pre-absorptive or cephalic phase reflexes/responses (CPR) and refer to a set of food intake-associated autonomic and endocrine responses to the stimulation of sensory systems mainly located in the oropharyngeal cavity. Their function may be essential adaptive, preparing the digestive system for the reception, digestion and absorption of ingested nutrients.
The release of cephalic phase hormones occurs through activation of vagal efferent fibers in response to food-related sensory stimuli. Pancreatic polypeptide (PP) is a hormone almost exclusively under vagal control increases. Thus, the cephalic phase PP response is a sensitive indicator of vagal activation to food stimuli. PP levels rise up to 100% above baseline when individuals taste, chew and expectorate food while the magnitude of cephalic phase insulin release is relatively small (25% above baseline). The cephalic phase is by some considered as a reflex rather then a response as it is dependent on neural rather than nutrient-induced stimulation.
The physiological significance of the cephalic phase hormonal responses is demonstrated by experimental manipulations which inhibit or bypass cephalic phase insulin release. Under these circumstances, hyperglycemia and hyperinsulinemia are evident.
Alcohol consumption lowers postprandial glucose concentrations and improves insulin secretion. Furthermore, alcohol consumption increases postprandial diet-induced thermogenesis, heart rate and causes diuresis presumably resulting from inhibition of vasopressin. Since in the postprandial state, almost all cephalic phase responses are affected by alcohol, it seems plausible that the human body might exhibit a CPR upon oral sensory stimulation by alcohol-containing beverages. This study therefore investigates for the first time if and to what extent alcohol triggers CPR which may account for the improved postprandial glycemia seen after alcohol consumption.
Gene expression in adipose tissue Application of transcriptomics technology, via gene expression profiling, with the use of microarrays is a powerful but expensive tool for identifying molecular pathways responsible for metabolic regulation. Gene expression profiling in human intervention studies, allows for genome wide screening of the effects of specific diets or nutrients and results in biomarker profiles. Recently, it has been used to detect new important signaling pathways involved in glucose and lipid metabolism.
Adipose tissue has important metabolic and endocrine functions. Changes in these functions are associated with an increased low-grade inflammatory state and with chronic diseases such as obesity and diabetes. Furthermore, changes in gene expression profiles of subcutaneous adipose tissue can be observed after nutritional interventions.
An important hormone almost exclusively and abundantly secreted by adipose tissue is adiponectin. Circulating adiponectin levels in lean persons are far above any other hormone. It is believed that these high levels of adiponectin protect lean persons while its decrease in obesity is associated with a low grade inflammation and the development of insulin resistance and diabetes. Research by our group has shown that moderate alcohol consumption increases both plasma levels and mRNA adiponectin levels. This suggests that moderate alcohol consumption, directly or indirectly, exerts effects on adipose tissue gene expression. Since adiponectin is associated with inflammatory status, lipid metabolism and insulin sensitivity, changes in gene expression of these pathways are expected after alcohol consumption to be reflected in adipose gene expression.
Beneficial effects of moderate alcohol consumption might be more apparent in lean then in overweight persons. Compared to overweight men, lean men have stronger increases in adiponectin and in the 'good' HDL cholesterol after moderate alcohol consumption. Furthermore, liver enzymes of obese subjects are elevated after moderate alcohol consumption indicating a less favorable response to moderate alcohol consumption among overweight persons. Since the current rise in the obesity pandemic, different responses between lean and obese subjects after alcohol consumption are of great importance.
Thus, investigating alcohol-induced changes in gene expression of adipose tissue in both lean and overweight subjects could not only be highly valuable for the identification of new biomarkers but could also be of pivotal importance to identify specific physiological mechanisms leading to improved insulin sensitivity and reduced inflammatory status. This eventually could help in the general understanding of the development of diet-related chronic disorders such as obesity and type two diabetes.
- Being tested
- alcohol, Placebo
- Keywords
- cephalic phase reflex, gene expression, inflammation, adiponectin, pancreatic polypeptide
- Medical subject headings
- Diabetes Mellitus, Type 2, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
alcoholDietary supplement
250 ml of white wine (13% vol; ~25 gram of alcohol per day)
PlaceboDietary supplement
250 ml of mineral water (Brand name: Vittel)
| Study group | Role | What they receive |
|---|---|---|
| treatment A | Experimental | four weeks of white wine consumption (25g alcohol/day; ~2.5 standard drinks) Receives: Dietary Supplement: alcohol |
| Treatment B | Placebo comparator | Four weeks of water Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gene expression profiles in adipose tissue
Measured: after four weeks of intervention
Pancreatic Polypeptide (PP)
Measured: 0, 4, 8, 12, 16, 20 and 30 min after start of modified sham-feeding with either water, white wine or cake
Secondary outcomes (1)
Cytokines excreted from PBMCs after in vitro stimulation with LPS
Measured: after four weeks of intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2008 (estimated)
- Study startMay 2008
- Primary completionJul 2008
- Study completionJul 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 24 participants (actual)
Sponsor and investigators
- Lead sponsor
- TNO
- Sponsor type
- University, hospital or other
- Investigators
- Henk FJ Hendriks, PhD, Principal investigator, TNO
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00652405
- Sponsor's protocol ID
- P8009
- Acronym
- AR22
- Status last verified
- May 2008
- First submitted
- 31 Mar 2008
- Last updated
- 11 Aug 2010
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Joosten MM, Balvers MG, Verhoeckx KC, Hendriks HF, Witkamp RF. Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women. Nutr Metab (Lond). 2010 Jun 14;7:49. doi: 10.1186/1743-7075-7-49.
PubMed 20546561Joosten MM, de Graaf C, Rietman A, Witkamp RF, Hendriks HF. Short-term oral exposure to white wine transiently lowers serum free fatty acids. Appetite. 2010 Aug;55(1):124-9. doi: 10.1016/j.appet.2010.04.217. Epub 2010 May 11.
PubMed 20438782
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Moderate Alcohol Consumption on Cephalic Phase Reflex and Gene Expression of Adipose Tissue in Postmenopausal Women
- ClinicalTrials.gov ID
- NCT00652405
- Acronym / sponsor ID
- AR22 / P8009
- Keywords
- cephalic phase reflex, gene expression, inflammation, adiponectin, pancreatic polypeptide
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 24 participants (actual)
- Lead sponsor
- TNOUniversity, hospital or other
- Study start
- May 2008
- Primary completion
- Jul 2008 (actual)
- Study completion
- Jul 2008 (actual)
- First posted
- 3 Apr 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Moderate alcohol consumption has consistently been associated with lowered risk of developing type two diabetes mellitus compared to abstainers and heavy drinkers. However, the underlying mechanism for the lower risk of type two diabetes is not clear.
Hypothesis: moderate alcohol consumption for four weeks changes gene expression pathways of inflammatory status, insulin sensitivity and lipid and carbohydrate metabolism in adipose tissue in both lean and obese postmenopausal women.
Hypothesis: Oral sensory stimulation by means of alcohol in the oral cavity will induce a cephalic phase reflex as indicated by increased autonomic \& endocrine responses in postmenopausal women.
Detailed description
Moderate alcohol consumption has consistently been associated with lowered risk of developing type two diabetes mellitus compared to abstainers and heavy drinkers. However, the physiological mechanism for this is not known.
Two potential mechanisms will be investigated in this study to explain the findings from observational studies: One concerning more acute changes upon alcohol consumption (cephalic phase reflex) which could explain the observed improvement in postprandial glycemia after alcohol consumption; the other has to do with metabolic changes after more prolonged moderate alcohol consumption in gene expression of adipose tissue which might lead to improved insulin sensitivity. Both mechanisms will be discussed below.
Cephalic phase reflex Mere exposure to smell, sight, taste and textural attributes of foods elicits myriad digestive, endocrinologic, thermogenic, cardiovascular and renal responses. These responses are rapid (generally occurring in minutes of sensory stimulation), small (relative to the magnitude achieved when food is actually being metabolized) and transient (retuning to baseline levels within minutes). They are termed pre-absorptive or cephalic phase reflexes/responses (CPR) and refer to a set of food intake-associated autonomic and endocrine responses to the stimulation of sensory systems mainly located in the oropharyngeal cavity. Their function may be essential adaptive, preparing the digestive system for the reception, digestion and absorption of ingested nutrients.
The release of cephalic phase hormones occurs through activation of vagal efferent fibers in response to food-related sensory stimuli. Pancreatic polypeptide (PP) is a hormone almost exclusively under vagal control increases. Thus, the cephalic phase PP response is a sensitive indicator of vagal activation to food stimuli. PP levels rise up to 100% above baseline when individuals taste, chew and expectorate food while the magnitude of cephalic phase insulin release is relatively small (25% above baseline). The cephalic phase is by some considered as a reflex rather then a response as it is dependent on neural rather than nutrient-induced stimulation.
The physiological significance of the cephalic phase hormonal responses is demonstrated by experimental manipulations which inhibit or bypass cephalic phase insulin release. Under these circumstances, hyperglycemia and hyperinsulinemia are evident.
Alcohol consumption lowers postprandial glucose concentrations and improves insulin secretion. Furthermore, alcohol consumption increases postprandial diet-induced thermogenesis, heart rate and causes diuresis presumably resulting from inhibition of vasopressin. Since in the postprandial state, almost all cephalic phase responses are affected by alcohol, it seems plausible that the human body might exhibit a CPR upon oral sensory stimulation by alcohol-containing beverages. This study therefore investigates for the first time if and to what extent alcohol triggers CPR which may account for the improved postprandial glycemia seen after alcohol consumption.
Gene expression in adipose tissue Application of transcriptomics technology, via gene expression profiling, with the use of microarrays is a powerful but expensive tool for identifying molecular pathways responsible for metabolic regulation. Gene expression profiling in human intervention studies, allows for genome wide screening of the effects of specific diets or nutrients and results in biomarker profiles. Recently, it has been used to detect new important signaling pathways involved in glucose and lipid metabolism.
Adipose tissue has important metabolic and endocrine functions. Changes in these functions are associated with an increased low-grade inflammatory state and with chronic diseases such as obesity and diabetes. Furthermore, changes in gene expression profiles of subcutaneous adipose tissue can be observed after nutritional interventions.
An important hormone almost exclusively and abundantly secreted by adipose tissue is adiponectin. Circulating adiponectin levels in lean persons are far above any other hormone. It is believed that these high levels of adiponectin protect lean persons while its decrease in obesity is associated with a low grade inflammation and the development of insulin resistance and diabetes. Research by our group has shown that moderate alcohol consumption increases both plasma levels and mRNA adiponectin levels. This suggests that moderate alcohol consumption, directly or indirectly, exerts effects on adipose tissue gene expression. Since adiponectin is associated with inflammatory status, lipid metabolism and insulin sensitivity, changes in gene expression of these pathways are expected after alcohol consumption to be reflected in adipose gene expression.
Beneficial effects of moderate alcohol consumption might be more apparent in lean then in overweight persons. Compared to overweight men, lean men have stronger increases in adiponectin and in the 'good' HDL cholesterol after moderate alcohol consumption. Furthermore, liver enzymes of obese subjects are elevated after moderate alcohol consumption indicating a less favorable response to moderate alcohol consumption among overweight persons. Since the current rise in the obesity pandemic, different responses between lean and obese subjects after alcohol consumption are of great importance.
Thus, investigating alcohol-induced changes in gene expression of adipose tissue in both lean and overweight subjects could not only be highly valuable for the identification of new biomarkers but could also be of pivotal importance to identify specific physiological mechanisms leading to improved insulin sensitivity and reduced inflammatory status. This eventually could help in the general understanding of the development of diet-related chronic disorders such as obesity and type two diabetes.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| treatment A | Experimental | Dietary Supplement: alcoholfour weeks of white wine consumption (25g alcohol/day; ~2.5 standard drinks) |
| Treatment B | Placebo comparator | Dietary Supplement: PlaceboFour weeks of water |
Who may qualify
- Ages
- Up to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (11 listed)
- Healthy as assessed by the health and lifestyle questionnaire (P8009 F02), physical examination and results of the pre-study laboratory tests
- Caucasian postmenopausal females aged 65 years or younger at Day 01 of the study.
- Body Mass Index (BMI) of 18 - 26 or 27 - 35 kg/m2.
- Postmenopausal as assessed by self reported absence of menstrual periods for at least 12 months.
- Alcohol consumption ≥ 5 and ≤ 22 standard units/week.
Key exclusion criteria (16 listed)
- Participation in any clinical trial including blood sampling and/or administration of substances up to 90 days before Day 01 of this study.
- Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of substances.
- Having a history of medical or surgical events that may significantly affect the study outcome, particularly metabolic or endocrine disease and gastrointestinal disorders.
- Use of medication that may affect the outcome of the study parameters.
- Having a family history of alcoholism.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| alcohol250 ml of white wine (13% vol; ~25 gram of alcohol per day) | Dietary supplement | treatment A |
| Placebo250 ml of mineral water (Brand name: Vittel) | Dietary supplement | Treatment B |
Primary outcome
Gene expression profiles in adipose tissue
Time frame: after four weeks of intervention
Pancreatic Polypeptide (PP)
Time frame: 0, 4, 8, 12, 16, 20 and 30 min after start of modified sham-feeding with either water, white wine or cake
1 secondary outcome
Cytokines excreted from PBMCs after in vitro stimulation with LPS
Time frame: after four weeks of intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2010.
- Results publication: PubMed 20546561Joosten MM, Balvers MG, Verhoeckx KC, Hendriks HF, Witkamp RF. Plasma anandamide and other N-acylethanolamines are correlated with their corresponding free fatty acid levels under both fasting and non-fasting conditions in women. Nutr Metab (Lond). 2010 Jun 14;7:49. doi: 10.1186/1743-7075-7-49.
- Results publication: PubMed 20438782Joosten MM, de Graaf C, Rietman A, Witkamp RF, Hendriks HF. Short-term oral exposure to white wine transiently lowers serum free fatty acids. Appetite. 2010 Aug;55(1):124-9. doi: 10.1016/j.appet.2010.04.217. Epub 2010 May 11.
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Henk FJ Hendriks, PhD principal investigator
TNO
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing alcohol in people with Type 2 Diabetes and Inflammation, run by TNO at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Aug 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gene expression profiles in adipose tissue (time frame: after four weeks of intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00652405, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2010.